Date | 28 February 2021 – present (2 years, 9 months, 3 weeks and 4 days) |
---|---|
Location | Thailand |
Cause | COVID-19 pandemic in Thailand |
Participants | 112,279,694 total doses (20 Jan 2022) [1] |
Website | ddc dashboard-vaccine |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
COVID-19 vaccination in Thailand is an ongoing mass immunization in response to the ongoing pandemic in the country.
In November 2020, the authorities ordered 26 million doses of vaccine from AstraZeneca, which reported 70% overall efficacy. [3] It requires 2 doses of vaccine per person, so the quantity ordered would only cover 13 million people. [4] Prayut cabinet later approved budget for ordering 35 million additional doses in January 2021. [5] Siam Bioscience, a company owned by King Vajiralongkorn, will received technological transfer for co-investment. [6] The authorities also imported 2 million doses of vaccine from Sinovac, a Chinese company which Thai conglomerate Charoen Pokphand invested in, [7] during February to April 2021. [8]
Likewise, the Thai government also stepped up its attempt to produce its homegrown vaccines amidst criticism, [9] with "ChulaCov19" and set to begin trials in May 2021. [10] Phase I testing of the NDV-HXP-S vaccine began at Mahidol University in March 2021. [11] [12]
In July 2021, the National Vaccine Institute apologized for slow vaccine deployment. [13] Meanwhile, the government's prior commitment to secure 61 million doses of AstraZeneca vaccine became doubted after a leaked document showed that the company would deliver no more than 60 percent of the number planned per month. [14] A virology advisor also endorsed an untested plan to mix AstraZeneca and Sinovac vaccines. [15] There was already a report of death from the practice, but health professionals said they have to rule out other causes first. [16]
Free Vaccines which are provided under the policies of the Ministry of Public Health.
Vaccine name | Doses ordered (excluding donation) | Doses arrived (including donation) | Approval (EUA) | First Arrival | Deployment | Ref |
---|---|---|---|---|---|---|
Oxford–AstraZeneca | 61 million | 25.5 million | 20 January 2021 | 24 February 2021 | 28 February 2021 | [17] [18] [19] [20] |
CoronaVac | 31.1 million | 26.52 million | 22 January 2021 | 24 February 2021 | 28 February 2021 | [18] [19] [20] |
Janssen | 5 million | unknown | 25 March 2021 | Late June | 26 July 2021 | [21] [22] [23] [24] [20] |
Pfizer–BioNTech | 30 million | 3.5 million | 24 June 2021 | 30 July 2021 | 5 Aug 2021 | [25] [26] [27] [18] [28] [29] |
Vaccines that are not in the policies of the Ministry of Public Health. Orders are made through government organizations but the cost of vaccination will not be supported by the government. However, people who get vaccinated by these vaccines are still counted in the national vaccination programme.
Vaccine name | Distributor | Doses planned or ordered | Doses arrived | Approval (EUA) | First Arrival | Deployment | Ref |
---|---|---|---|---|---|---|---|
Moderna | Government Pharmaceutical Organization | 5 million | 0.5602 million | 13 May 2021 | 1 Nov 2021 | 5 Nov 2021 | [21] [30] [31] [32] |
Chulabhorn Royal Academy | 8 million | Not yet | 13 May 2021 | Not yet | Not yet | [33] | |
Sinopharm BIBP (BBIBP-CorV) | Chulabhorn Royal Academy | 15 million | 15 million | 28 May 2021 | 20 June 2021 | 25 June 2021 | [21] [34] [35] [18] [36] [37] |
Vaccination procedures used in Thailand. [38]
Vaccine | Type (technology) | Progress |
---|---|---|
NDV-HXP-S (HXP-GPOVac) Mahidol University, University of Texas at Austin, | Newcastle disease virus (NDV) viral vector (expressing the spike protein of SARS-CoV-2, with or without the adjuvant CpG 1018) or Inactivated | Phase I–II (460) Randomized, placebo-controlled, observer-blind. Mar 2021 –May 2022; Thailand [43] |
ChulaCov19 Chulalongkorn University | RNA | Phase I–II (96) Dose-finding Study. Jan–Mar 2021, Thailand |
Baiya SARS-CoV-2 Vax 1 [45] Baiya Phytopharm Co Ltd. | Plant-based Subunit (RBD-Fc + adjuvant) | Phase I (96) Randomized, open-label, dose-finding. Sep–Dec 2021, Thailand |
COVIGEN [47] Bionet Asia, Technovalia, University of Sydney | DNA | Phase I (150) Double-blind, dose-ranging, randomised, placebo-controlled. Feb 2021 –Jun 2022, Australia, Thailand |
Yong Poovorawan is a professor of pediatrics at the Faculty of Medicine of Chulalongkorn University in Bangkok, Thailand. He is known for research in the fields of pediatric hepatology, viral hepatitis and virology, and avian influenza.
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. Developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.
CoronaVac, also known as the Sinovac COVID-19 vaccine, is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was phase III clinically trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine, and Covaxin, an Indian vaccine. CoronaVac does not need to be frozen, and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), the temperatures at which flu vaccines are kept.
The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a day after the arrival of the country's first vaccine doses which were donated by the Chinese government.
The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all willing people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.
The COVID-19 vaccination campaign in Albania is a mass immunization campaign that was put in place by the Albanian authorities in order to respond to the ongoing COVID-19 pandemic. It started on 11 January 2021.
COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The virus causing COVID-19 was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.
The National Advisory Committee on Immunization is an advisory body that provides the Government of Canada with medical and scientific advice relating to human immunization.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.
NDV-HXP-S is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai.
COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.
The COVID-19 vaccination campaign in Brazil is an ongoing mass immunization campaign for the COVID-19 pandemic in Brazil. It started on January 17, 2021, when the country had 210 thousand deaths.
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country.